Cargando…

Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis

PURPOSE: Primary hyperparathyroidism (PHPT) is characterized by increased bone remodeling and hypercalcemia. Parathyroidectomy (PTX), the current standard of care, is recommended in all symptomatic and some groups of asymptomatic patients. Anti-resorptive therapies (bisphosphonates and denosumab) ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajput, Swati, Dutta, Aditya, Rajender, Singh, Mithal, Ambrish, Chattopadhyay, Naibedya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931892/ https://www.ncbi.nlm.nih.gov/pubmed/36817591 http://dx.doi.org/10.3389/fendo.2023.1098841

Ejemplares similares

Denosumab for management of severe hypercalcemia in primary hyperparathyroidism
por: Eremkina, Anna, et al.
Publicado: (2020)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

Lithium-induced Hyperparathyroidism and Hypercalcemia
por: Naramala, Srikanth, et al.
Publicado: (2019)

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents
por: Rodriguez-Lozano, Francisco-Javier, et al.
Publicado: (2016)

Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment
por: Hu, Mimi I., et al.
Publicado: (2013)

MON-335 Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?
por: Patel, Reshma, et al.
Publicado: (2020)

Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report
por: Roukain, Abdallah, et al.
Publicado: (2022)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review
por: Camponovo, C., et al.
Publicado: (2020)

Symptomatic Rebound Hypercalcemia After Denosumab Discontinuation in a Pediatric Patient With Cherubism
por: Marpuri, Ian, et al.
Publicado: (2021)

The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy
por: Kincse, Gyöngyvér, et al.
Publicado: (2012)

Parathyromatosis Recurrent Hyperparathyroidism and Refractory Hypercalcemia Successfully Managed With Addition of Denosumab: A Case Report
por: Alhammad, Zahrah Abbas, et al.
Publicado: (2021)

ODP084 Denosumab as a therapuetic modality in management of primary hyperparathyroidism induced severe hypercalcemia
por: Mangaraj, Swayamsidha, et al.
Publicado: (2022)

Concurrent Primary Hyperparathyroidism and Sarcoidosis in a Patient With Severe Hypercalcemia
por: Ayyad, Mohammed, et al.
Publicado: (2023)

Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism
por: Kuchay, Mohammad Shafi, et al.
Publicado: (2021)

PB2142: SERUM OSTEOCALCIN AS A PREDICTOR FOR THE RISK OF DENOSUMAB AND BISPHOSPHONATE INDUCED HYPOCALCEMIA IN MYELOMA PATIENTS WITH HYPERCALCEMIA
por: Ding, Yuehua, et al.
Publicado: (2023)

Hypercalcemia due to Co-Occurring Metastatic Breast Cancer and Primary Hyperparathyroidism
por: Khubaib, Mohammad U, et al.
Publicado: (2021)

Hormonal and non-hormonal oral contraceptives given long-term to pubertal rats differently affect bone mass, quality and metabolism
por: Porwal, Konica, et al.
Publicado: (2023)

Denosumab as a Bridge to Surgery in a Patient with Severe Hypercalcemia Due to Primary Hyperparathyroidism in the Setting of Renal Dysfunction
por: Rajan, Remya, et al.
Publicado: (2019)

Single Dose of Denosumab Effective for Management of Bisphosphonate-Refractory Hypercalcemia of Malignancy Related to Non-Small Cell Lung Cancer
por: Dinh, Kathryn, et al.
Publicado: (2021)

A novel extraction method enhanced the osteogenic and anti-osteoporosis effect of tea extract without any hepatotoxicity in ovariectomized rats
por: Kulkarni, Chirag, et al.
Publicado: (2022)

SAT-499 Denosumab for Treatment of Hypercalcemia in Myelofibrosis
por: Wong, Beatrice, et al.
Publicado: (2019)

Humoral hypercalcemia of pregnancy treated with bisphosphonates
por: Koren, Ronit, et al.
Publicado: (2018)

Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair: A review
por: Qayoom, I., et al.
Publicado: (2018)

A Rare Case of Primary Hyperparathyroidism and Hypercalcemia of Malignancy Seen in a Patient With Prostate Adenocarcinoma
por: Jatoi, Asiya, et al.
Publicado: (2023)

A standardized extract of Coleus forskohlii root protects rats from ovariectomy-induced loss of bone mass and strength, and impaired bone material by osteogenic and anti-resorptive mechanisms
por: Kulkarni, Chirag, et al.
Publicado: (2023)

Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis
por: Reginster, J. Y., et al.
Publicado: (2014)

Administration of bisphosphonate for hypercalcemia associated with oral cancer
por: Onizawa, Kojiro, et al.
Publicado: (2006)

Future of bisphosphonates and denosumab for men with advanced prostate cancer
por: Iranikhah, Maryam, et al.
Publicado: (2014)

Can denosumab be a substitute, competitor, or complement to bisphosphonates?
por: Kim, Su Young, et al.
Publicado: (2017)

Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Horiuchi, Keisuke, et al.
Publicado: (2021)

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
por: Abd Jalil, Afdhal Afiq, et al.
Publicado: (2021)

SAT-359 Hypercalcemia - Is This Sarcoidosis, Hyperparathyroidism, or Both?
por: Veeramachaneni, Ravali, et al.
Publicado: (2020)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

SAT-502 Bisphosphonates for Treatment of Calcitriol-Induced Hypercalcemia
por: Mateo, Roselyn Cristelle, et al.
Publicado: (2019)

MON-258 Toddler with Hypercalcemia: Diagnosis of Familial Hypocalciuric Hypercalcemia
por: Kochanski, Justin, et al.
Publicado: (2019)

Familial Hyperparathyroidism
por: Blau, Jenny E., et al.
Publicado: (2021)

Cancer-related hypercalcemia and potential treatments
por: Almuradova, Elvina, et al.
Publicado: (2023)

Osteoporosis Therapy With Denosumab in Organ Transplant Recipients
por: Brunova, Jana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_92ds1knr0ea3pjgq0658hdd6tg